*. Yondelis Provided 27.5% Objective Response, and 61.2% Clinical Benefit in Recurrent Ovarian Cancer ( ROC ) Patients .
*.- Trabectedin was more effective in platinum sensitive recurrent ovarian cancer patients.
*.- Trabectedin shows acceptable toxicity in heavily treated recurrent ovarian cancer patients.
Conclusions :
Trabectedin, as a single agent, retains its efficacy in terms of rate of ORR and clinical benefit in heavily treated ROC patients, especially in the group of platinum sensitive disease.
...